Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Liraglutide181 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00251 | 35164657 | Bioengineered | Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. | 2022 | Details |
| A00267 | 35160204 | J Clin Med | Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A01668 | 34660809 | J Diabetes Res | Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A02287 | 34435378 | Aliment Pharmacol Ther | Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. | 2021 | Details |
| A02349 | 34406410 | J Clin Endocrinol Metab | The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. | 2022 | Details |
| A03013 | 34164242 | Cureus | Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. | 2021 | Details |
| A03159 | 34107584 | Zhonghua Gan Zang Bing Za Zhi | [Liraglutide alleviates lipotoxic liver cell damage and promotes autophagy to improve non-alcoholic fatty liver]. | 2021 | Details |
| A03282 | 34062416 | Biomed Pharmacother | The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis. | 2021 | Details |
| A03289 | 34059612 | Curr Opin Cardiol | Update on cardiovascular risk in nonalcoholic fatty liver disease. | 2021 | Details |
| A03385 | 34022222 | J Biol Chem | Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. | 2021 | Details |
| A03431 | 34002333 | Diabetes Ther | Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. | 2021 | Details |
| A03840 | 33852508 | Eur J Gastroenterol Hepatol | The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. | 2022 | Details |
| A03843 | 33851458 | Hepatology | Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. | 2021 | Details |
| A03861 | 33841337 | Front Endocrinol (Lausanne) | Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis. | 2021 | Details |
| A04016 | 33788377 | Liver Int | Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. | 2021 | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | 2021 | Details |
| A04128 | 33746742 | Front Pharmacol | Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway. | 2021 | Details |
| A04163 | 33732030 | Clin Pharmacol | Clinical Impact of Liraglutide as a Treatment of Obesity. | 2021 | Details |
| A04706 | 33534958 | ESC Heart Fail | Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. | 2021 | Details |
| A04749 | 33515800 | Ann Hepatol | Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. | 2021 | Details |
| A04758 | 33513761 | Metabolites | Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. | 2021 | Details |
| A04853 | 33482185 | Life Sci | Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. | 2021 | Details |
| A04924 | 33447122 | Clin Med Insights Endocrinol Diabetes | Oral GLP1 Analog: Where Does the Tide Go? | 2020 | Details |
| A05119 | 33368954 | Diabetes Obes Metab | Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. | 2021 | Details |
| A05156 | 33352183 | Eur J Pharmacol | The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. | 2020 | Details |
| A05215 | 33336025 | Open Med (Wars) | Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet. | 2020 | Details |
| A05230 | 33330497 | Front Cell Dev Biol | Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway. | 2020 | Details |
| A05297 | 33309563 | Clin Res Hepatol Gastroenterol | Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. | 2020 | Details |
| A05793 | 33115209 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. | 2020 | Details |
| A05843 | 33102775 | JGH Open | Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. | 2020 | Details |
| A06026 | 33036179 | J Clin Med | One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. | 2020 | Details |
| A06027 | 33035599 | Diabetes Res Clin Pract | Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. | 2020 | Details |
| A06165 | 32981283 | Zhongguo Ying Yong Sheng Li Xue Za Zhi | [Effects of liraglutide combined with vitamin D on non-alcoholic fatty liver induced by high fat in mice and its mechanism]. | 2020 | Details |
| A06230 | 32961563 | Exp Clin Endocrinol Diabetes | Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model. | 2020 | Details |
| A06232 | 32961235 | Life Sci | Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice. | 2020 | Details |
| A06309 | 32933722 | Tissue Cell | Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats. | 2020 | Details |
| A06475 | 32865597 | Diabetologia | Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). | 2020 | Details |
| A06658 | 32791578 | Clin Mol Hepatol | Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. | 2020 | Details |
| A06675 | 32785012 | Int J Mol Sci | Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A06717 | 32771373 | Peptides | Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway. | 2020 | Details |
| A06882 | 32711187 | Transl Res | The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. | 2020 | Details |
| A06965 | 32684739 | World J Gastroenterol | Medications in type-2 diabetics and their association with liver fibrosis. | 2020 | Details |
| A06984 | 32673798 | Mol Metab | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. | 2020 | Details |
| A07203 | 32583961 | Clin Transl Sci | Evolving Role for Pharmacotherapy in NAFLD/NASH. | 2020 | Details |
| A07440 | 32496108 | Rev Esp Enferm Dig | The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. | 2020 | Details |
| A07480 | 32478287 | Nat Metab | Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. | 2020 | Details |
| A07726 | 32375182 | Horm Metab Res | Liraglutide Ameliorates Lipotoxicity-Induced Oxidative Stress by Activating the NRF2 Pathway in HepG2 Cells. | 2020 | Details |
| A07888 | 32322207 | Front Pharmacol | Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System. | 2020 | Details |
| A08219 | 32196896 | Diabetes Obes Metab | Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. | 2020 | Details |
| A08276 | 32171530 | Biochem Biophys Res Commun | Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway. | 2020 | Details |
| A08337 | 32149099 | Biomed Res Int | Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet. | 2020 | Details |
| A08431 | 32113823 | Clin Res Hepatol Gastroenterol | Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. | 2020 | Details |
| A08963 | 31923578 | Diabetes Metab | Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. | 2020 | Details |
| A09074 | 31883514 | BMC Gastroenterol | Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. | 2019 | Details |
| A09247 | 31819375 | Drug Des Devel Ther | Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways. | 2019 | Details |
| A09333 | 31787541 | Ann Hepatol | The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy. | 2019 | Details |
| A09343 | 31783920 | Syst Rev | Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. | 2019 | Details |
| A09573 | 31690988 | Diabetologia | Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. | 2019 | Details |
| A09842 | 31593687 | Eur J Pharmacol | Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. | 2019 | Details |
| A09978 | 31538291 | Endocrine | Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. | 2019 | Details |
| A10167 | 31460789 | Am J Physiol Gastrointest Liver Physiol | Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis. | 2019 | Details |
| A10249 | 31412267 | Eur J Pharmacol | Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways. | 2019 | Details |
| A10448 | 31333877 | Clin Diabetes Endocrinol | Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time. | 2019 | Details |
| A10476 | 31321014 | Ther Adv Chronic Dis | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. | 2019 | Details |
| A10507 | 31308717 | Diabetes Metab Syndr Obes | Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway. | 2019 | Details |
| A10676 | 31241045 | Gen Physiol Biophys | Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers. | 2019 | Details |
| A10687 | 31236111 | Int J Endocrinol | Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway. | 2019 | Details |
| A10807 | 31180545 | Mol Med Rep | LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet. | 2019 | Details |
| A11071 | 31058888 | J Vis Exp | Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution. | 2019 | Details |
| A11125 | 31031702 | Front Endocrinol (Lausanne) | The Discovery and Development of Liraglutide and Semaglutide. | 2019 | Details |
| A11226 | 30986904 | Int J Mol Sci | Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis. | 2019 | Details |
| A11520 | 30861258 | Hepatol Res | Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention. | 2019 | Details |
| A11557 | 30841472 | Biomed Pharmacother | Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. | 2019 | Details |
| A11803 | 30734333 | Hepatology | Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. | 2019 | Details |
| A11810 | 30729549 | Hepatology | Reply. | 2019 | Details |
| A11818 | 30721572 | Liver Int | Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. | 2019 | Details |
| A11916 | 30683312 | Biochem Biophys Res Commun | Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway. | 2019 | Details |
| A12000 | 30652641 | Curr Pharm Des | Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome. | 2018 | Details |
| A12156 | 30578967 | Biochim Biophys Acta Mol Cell Biol Lipids | Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. | 2018 | Details |
| A12386 | 30473540 | Biosci Rep | Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. | 2018 | Details |
| A12514 | 30413050 | Pharmaceuticals (Basel) | Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? | 2018 | Details |
| A12659 | 30341767 | Hepatology | Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A12690 | 30325900 | Med Sci Monit | Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease. | 2018 | Details |
| A12778 | 30292107 | J Nutr Biochem | Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. | 2018 | Details |
| A12819 | 30269815 | Biochem Biophys Res Commun | Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet. | 2018 | Details |
| A13075 | 30149145 | Diabetes Metab | SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. | 2018 | Details |
| A13139 | 30120555 | Pflugers Arch | Catalase and nonalcoholic fatty liver disease. | 2018 | Details |
| A13228 | 30074500 | Curr Opin Endocrinol Diabetes Obes | Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. | 2018 | Details |
| A13230 | 30073766 | Diabetes Obes Metab | Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. | 2018 | Details |
| A13250 | 30064623 | Ugeskr Laeger | [Treatment of non-alcoholic fatty liver disease]. | 2018 | Details |
| A13467 | 29957886 | J Diabetes Investig | Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. | 2018 | Details |
| A13487 | 29953740 | Basic Clin Pharmacol Toxicol | Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis. | 2018 | Details |
| A13643 | 29858843 | Hormones (Athens) | The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). | 2018 | Details |
| A14182 | 29547706 | Atherosclerosis | Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. | 2018 | Details |
| A14513 | 29375204 | World J Gastroenterol | Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. | 2018 | Details |
| A14678 | 29290651 | World J Gastroenterol | miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. | 2017 | Details |
| A14850 | 29204050 | World J Gastroenterol | Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. | 2017 | Details |
| A15013 | 29128056 | Clin Liver Dis | Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. | 2017 | Details |
| A15682 | 28763870 | Zhonghua Gan Zang Bing Za Zhi | [Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances]. | 2017 | Details |